Lilly Oncology Support Center home
  • Prescribing Information
  • Patient Prescribing Information
Menu closed
Lilly Oncology Support Center home
  • Prescribing Information
  • Patient Prescribing Information
  • For Patients
    • CYRAMZA® (ramucirumab)
    • ERBITUX® (cetuximab)
    • Jaypirca® (pirtobrutinib)
    • Retevmo® (selpercatinib)
    • Verzenio® (abemaciclib)
  • For Healthcare Providers
    • Support and Resources
  • Contact Us
Globe Loading... Reveal available languages

Lilly Support Services for Oncology Sitemap

For Patients

For Patients Home

  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Jaypirca® (pirtobrutinib)
  • Retevmo® (selpercatinib)
  • Verzenio® (abemaciclib)

For Healthcare Providers

For Healthcare Providers Home

  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Jaypirca® (pirtobrutinib)
  • Retevmo® (selpercatinib)
  • Verzenio® (abemaciclib)
  • Support and Resources

Contact Us

Terms of Use
Privacy Statement
Consumer Health Privacy Notice
Accessibility Statement
Sitemap

To speak to customer support:
Call 1-800-LillyRx (1-800-545-5979)
Monday - Friday, 8am — 10pm ET

This site is intended for US residents ages 18 and over.

PP-OC-US-0369 12/2024 ©Lilly USA, LLC 2024. All rights reserved.

CYRAMZA®, ERBITUX®, Retevmo®, Verzenio®, Jaypirca®, and Lilly Cares® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly Support Services™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Other product/company names mentioned herein are the property of their respective owners.

Your Privacy Choices

Cookie Settings

Terms of UsePrivacy StatementConsumer Health Privacy NoticeAccessibility StatementSitemap
Visit Lilly.com